A

AbbVie

Global biopharmaceutical company developing medicines

Specialty Representative - Psychiatry

Full-Time
$78.5k - $192.5k/yr+ Short-term incentive programs
Senior
Bachelor's
Columbia, MO, USA
RemoteCandidates must live within a reasonable distance from Columbia, MO.
Sales & Account ManagementField Sales

About the job

Requirements
  • Bachelor’s degree in health, sciences, pharmacy or business-related field preferred or relevant and equivalent industry experience required
  • Relevant and equivalent industry experience required in lieu of a bachelor’s degree is at least five (5) years of experience with three (3) or more years of experience within the pharmaceutical/health/science industry preferred and a high school diploma/GED required
  • Proven track record of leadership success and solid presentation skills. Strong business acumen and proficient use of business tools; possesses strategic and critical thinking capabilities.
  • An essential requirement of your position is to satisfy all applicable health care industry representative (HCIR) credentialing requirements to gain and maintain entry into facilities and organizations that are in your assigned territory.
  • Valid driver’s license: Ability to pass a pre-employment drug screening test and meet safe driving requirements.
Responsibilities
  • Execute brand strategy and tactics in field, sales performance, effectively manage assigned territory and targeted accounts, build strong customer relationships and customer needs solving capability to maximize short and long term sales performance placing the patient into the center of any efforts and operating within AbbVie’s business code of conduct, policies and all applicable laws and regulations.
  • Deliver sales performance, brand KPIs, financial targets, marketing objectives, etc. to meet or exceed on those objectives.
  • Create pre-call plan objectives and execute post-call evaluation to continuously improve sales performance. Effectively handle objections, misunderstandings, concerns and consistently gain logical and reasonable calls to action to close on every sales call.
  • Proactively and continuously aspire to serve customer needs, customer expectations and challenges to build trusted customer relationships and to achieve win-win agreements between AbbVie and customers
  • Develop and execute a call plan that achieves set call metrics and optimizes coverage and frequency to key customers to maximize access and sales opportunities.
  • Continuously build understanding on customer needs and expectations, territory market landscape, competitors, market segments/dynamics, accounts, disease, product, clinical and sales expertise and share this market intelligence information with in-field team, brand team and sales manager to achieve alignment, to anticipate environmental changes and challenges and to optimize brand strategy and its execution.
  • Differentiate AbbVie’s value proposition with health providers assigned and identify, develop, and maintain disease state experts and speakers/advocates to maximize brand performance
Desired Qualifications
  • Proven track record of leadership success and solid presentation skills. Strong business acumen and proficient use of business tools; possesses strategic and critical thinking capabilities.
  • Proactively identifies customer style / behavior and adapts quickly all aspects of selling approach. Operates effectively in a matrix environment.
  • Preferred: Proven track record of success in sales performance within respective therapeutic areas.
  • Preferred: Commercial pharmaceutical industry experiences such as physician/account based selling, training, managed health care or marketing preferred.
  • Preferred: Demonstrates in-depth scientific, therapeutic, product, and competitive knowledge and is recognized as an expert resource by all relevant stakeholders
  • Preferred: English language proficiency verbally and in writing (for all non-English speaking countries).

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 13th, 2026
AbbVie vs Novo Nordisk: AbbVie's $61.2B revenue growth makes it the better 2026 buy

A Motley Fool comparison of AbbVie and Novo Nordisk concludes AbbVie is the better long-term buy in 2026, even though Novo looks cheaper. AbbVie's 2025 revenue rose about 8.6% to $61.2 billion, but net income was $4.2 billion. Novo Nordisk's revenue grew 6.4% to $46.3 billion, with net income of $15.3 billion. Novo trades at 11.7 times forward earnings against AbbVie's 20.2. Analysts expect Novo's 2026 sales to fall about 3% on pricing pressure and rivalry from Eli Lilly. AbbVie is forecast to grow net income to $14.6 billion on $67.2 billion in sales, helped by its $10.9 billion Apogee Therapeutics deal and its Skyrizi and Rinvoq drugs.

Yahoo Finance
Oct 13th, 2026
AbbVie shares at $281.12 trade 43.5% below DCF fair value of $497.77 after pipeline wins

AbbVie shares have climbed to $281.12, up 9.33% in a month and 22.59% so far this year, after a run of clinical and regulatory news. Total shareholder return is 25.85% over one year. The news includes Phase 3 Crohn's disease results for SKYRIZI and RINVOQ, and FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer. AbbVie also released early obesity data for ABBV-295 and Phase 2 atopic dermatitis results for zumilokibart. Simply Wall St's most followed narrative puts fair value at $278.61, leaving the stock 1% overvalued. Its discounted cash flow model estimates $497.77, which would put the shares about 43.5% below fair value. Risks include tighter drug price pressure and faster than expected competition for Skyrizi and Rinvoq.

Yahoo Finance
Oct 13th, 2026
AbbVie vs Eli Lilly: Lilly's 44.7% revenue surge to $65.2B makes it the 2026 pick

A comparison of AbbVie and Eli Lilly favours Eli Lilly for long-term investors, driven by its strong weight-loss and diabetes drug franchise. Lilly's 2025 revenue rose 44.7% to $65.2 billion, with net income of $20.6 billion. AbbVie's revenue grew 8.6% to $61.2 billion, with net income of $4.2 billion, as Skyrizi and Rinvoq replace ageing Humira sales. Lilly trades at a forward price-to-earnings ratio of 33.1x, against 19.8x for AbbVie. Lilly expects 2026 revenue of up to $85.2 billion, helped by Zepbound, Mounjaro and a new pill, Foundayo. AbbVie forecasts 2026 sales of $67.2 billion and net income of $14.6 billion. It is also acquiring Apogee Therapeutics.

Finanzen.net
Oct 12th, 2026
S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated.

S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated. October 12, 2026, 4:00 p.m. Invested in AbbVie years ago: This is how much investors would have earned. Exactly 10 years ago today, trading in the AbbVie share took place on the NYSE. The stock ended the day at USD 61.21. With a USD 100 investment 10 years ago, investors would now have 1.634 AbbVie shares in their portfolio. Calculated using the most recent closing price from October 9, 2026 (USD 276.47), the investment would now be worth USD 451.67. That means the value of the original investment would have increased by 351.67 percent. The market value of AbbVie recently amounted to USD 487.20 billion. Please note that stock splits and dividend payments are not taken into account in the above calculation. finanzen.net editorial team Selected leveraged products on AbbVie. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on AbbVie. | Name | Leverage | KO | Issuer | | Mini Future Long on AbbVie | 4.72 | 239.26 | Morgan Stanley | | Turbo Long on AbbVie | 4.60 | 219.21 | Morgan Stanley | | Mini Future Long on AbbVie | 4.51 | 234.17 | Morgan Stanley | | Turbo Long on AbbVie | 4.31 | 215.06 | Morgan Stanley | | Turbo Long on AbbVie | 4.05 | 210.62 | Morgan Stanley | You can obtain the base prospectus as well as the final terms and the key information documents here: MR42P0, MR2ECS, MR42NZ, MR14JZ, MN9YRD. Please also note the further information** on this advertisement. Risk notice: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.

Yahoo Finance
Oct 11th, 2026
AbbVie's yield hits 2.6%, its lowest since 2018, but dividend growth keeps it an income pick

AbbVie's dividend yield has fallen to about 2.6%, its lowest since early 2018. The drop comes from a share price that has risen faster than the dividend, not from any cut. The drugmaker has raised its dividend for 54 consecutive years, including its time as part of Abbott Labs. The payout is up almost 333% since 2013, while the stock has gained roughly 676%. Growth looks set to continue. Humira's successors, Skyrizi and Rinvoq, are on track for combined 2026 sales of over $29 billion, against Humira's peak of about $22 billion in 2021. If dividend growth matches the past five years' pace, yield on cost could top 4.6% within 10 years. Consensus analyst targets imply only about 5% upside over 12 months.